Athersys Shares Jump After MultiStem Cell Therapy Data Published In Medical Journal

Athersys Inc ATHX announced that a manuscript reporting data from its MUST-ARDS clinical trial have been published in the peer-reviewed medical journal, Intensive Care Medicine. 

  • MUST-ARDS Phase 1/2 trial evaluated the safety and efficacy of MultiStem (invimestrocel) cell therapy in patients with acute respiratory distress syndrome (ARDS). 
  • MultiStem treatment was well-tolerated, with no allergic or serious adverse reactions associated with the cell therapy in any cohort through one year of follow-up.
  • Notably, higher median ICU-free and ventilator-free days (VFDs) were seen among MultiStem cell recipients than the placebo group at the 28-day benchmark.
  • Lower all-cause mortality in the MultiStem-treatment group was observed compared to the placebo group;
  • Quality of Life outcomes showed greater recovery among survivors who received MultiStem treatment than those who received placebo.
  • Decreases in several pro-inflammatory plasma biomarkers were observed in the cell treatment group through Day 7 compared with increases among placebo recipients.
  • In addition, preliminary analyses (not reported in the published manuscript) of the data pooled from the MUST-ARDS study and the recently completed ONE-BRIDGE study further support the potential clinically meaningful benefit of MultiStem for ARDS. 
  • Analysis revealed an estimate of 5.4 greater VFDs among MultiStem recipients compared to the control group. 
  • Price Action: ATHX shares are up 7.35% at $1.09 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!